EP.08.38 Real-World Data of Adjuvant Therapy With Aumolertinib for EGFR-Mutated NSCLC Patients
Huan Liu(Xiamen University), Xiangyu Yan(Tianjin University), Hubin Duan(Shanxi Medical University), Ke Chen(Tongji Hospital), Xiaoyu Dong(Nanfang Hospital), K. Zhang(People 's Liberation Army 451 Hospital), Liping Tong(Shanghai Dianji University), Y. Zhang(People 's Liberation Army 451 Hospital)
Cited by 0
Related Papers
SPOP Promotes Tumorigenesis by Acting as a Key Regulatory Hub in Kidney Cancer
|Cancer Cell|2014|180
Interferon regulatory factor 3 constrains IKKβ/NF-κB signaling to alleviate hepatic steatosis and insulin resistance
|Hepatology|2013|157
Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer
|Clinical Cancer Research|2016|125
TRAF1 is a critical regulator of cerebral ischaemia–reperfusion injury and neuronal death
|Nature Communications|2013|113
Study protocol: A cross-sectional study on psychology and behavior investigation of Chinese residents, PBICR
|Psychosomatic Medicine Research|2022|94